TScan Therapeutics Announces Positive Updated Data from the ALLOHA Phase 1 Heme Trial at the 67th American Society of Hematology Annual Meeting and Exposition Life Science Investing
Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025 Life Science Investing
Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm Programs Life Science Investing
Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia at the 67th American Society of Hematology Annual Meeting & Exposition Life Science Investing
Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel Highlighting Durable, Differentiated Profile in Sickle Cell Disease at American Society of Hematology Annual Meeting Life Science Investing
Kymera Therapeutics to Announce KT-621 BroADen Phase 1b Atopic Dermatitis Trial Results on December 8, 2025 Life Science Investing
Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society Annual Meeting Life Science Investing
Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points Life Science Investing
Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During "J.P. Morgan Week 2026" Life Science Investing
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement Life Science Investing
Covalon Announces Conference Call to Discuss Fourth Quarter and Year End Fiscal 2025 Financial Results Life Science Investing
